Illumina Signs SNP Genotyping Agreement With the University of Cambridge, UK; BeadArray Technology Will Help Correlate SNP Genotypes With Diabetes.Business Editors & Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--Aug. 27, 2002 Illumina, Inc. announced today that it has signed a commercial agreement with the University of Cambridge (UK) to provide single nucleotide polymorphism Noun 1. single nucleotide polymorphism - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily successful enough to recur in a (SNP SNP Scottish National Party Noun 1. SNP - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily ) genotyping services on a sample collection provided by the University's Cambridge Institute for Medical Research (CIMR CIMR Cambridge Institute for Medical Research CIMR Caisse Interprofessionnelle Marocaine de Retraites CIMR Cornell Institute for Medical Research ), which houses the Juvenile Diabetes Research Foundation The Juvenile Diabetes Research Foundation (JDRF) is the leading charitable funder and advocate of type 1 (juvenile) diabetes research worldwide. The mission of JDRF is to find a cure for diabetes and its complications through the support of research. and Wellcome Trust funded Diabetes and Inflammation Laboratory (JDRF/WT DIL DIL - Dual In-Line Package ). Under the terms of the agreement, Illumina will design functional assays for the SNP loci provided by CIMR, and then use its BeadArray(TM) technology to genotype specified SNPs in the set of roughly 3000 samples. Further details about the agreement were not disclosed. Researchers at the JDRF/WT DIL have already contributed to the discovery of three of the genes associated with type 1 (autoimmune inflammatory insulin-dependent) diabetes. The Institute aims to further understand the functional consequences of disease-associated variants and identify additional genes in the search for therapeutic opportunities based on disease mechanism and genotype. Jay Flatley, Illumina President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , noted, "The University's JDRF/WT DIL has helped pioneer the approach of integrating molecular medicine techniques with genetics, bioinformatics, and microarray technologies to improve investigative outcomes. We're pleased that the JDRF/WT DIL will be evaluating our technology and leveraging the speed and throughput of our BeadArray technology to further its diabetes research." Organizations such as the University of Cambridge and its CIMR are expanding the scale of research devoted to identifying and studying genetic variations (SNPs), the frequency of which may vary between normal and diseased individuals thereby implicating im·pli·cate tr.v. im·pli·cat·ed, im·pli·cat·ing, im·pli·cates 1. To involve or connect intimately or incriminatingly: evidence that implicates others in the plot. 2. specific genes and pathways in disease, which may point the way to improved diagnostic and therapeutic development. The diabetes research efforts of CIMR investigators are systematically integrated and facilitated by a special partnership of the Juvenile Diabetes Research Foundation and the Wellcome Trust (http://www-gene.cimr.cam.ac.uk/todd/; www.jdrf.org; www.wellcome.ac.uk). Illumina (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ILMN; www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray(TM) technology can provide the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. Illumina's technology will have applicability across a wide variety of industries beyond life sciences and pharmaceuticals, including agriculture, food, chemicals and petrochemicals. "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements are Illumina's ability to further develop its core BeadArray technologies and Oligator oligonucleotide manufacturing technologies to deliver timely and accurate genotyping service results. Illumina's ability to effectively market its genotyping systems, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion